Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $114 price target.

February 15, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Ultragenyx Pharmaceutical with a $114 price target.
The reiteration of an Overweight rating and maintenance of a $114 price target by a reputable analyst firm like Cantor Fitzgerald could instill confidence among investors and potentially lead to a positive short-term impact on Ultragenyx Pharmaceutical's stock price. Analyst ratings and price targets are closely watched by investors as indicators of a stock's future performance.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90